文献速递肝病消化道肿瘤与早癌

CTNNB1或AXIN1突变驱动肝癌发生过程中Hippo级联的不同需求

Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
PubMed 文献 · Hepatology · 2022-10-18

该研究利用条件性Yap、Taz及Yap;Taz敲除小鼠,分析YAP/TAZ在c-Met/β-Catenin与c-Met/sgAxin1驱动肝癌中的需求。结果显示YAP/TAZ在c-Met/sgAxin1肝癌中强烈诱导且为肿瘤发生与进展所必需,而c-Met/β-Catenin肝癌主要依赖YAP。AXIN1结合YAP/TAZ并调控其稳定性;tankyrase抑制剂G007-LK与c-MET抑制剂卡博替尼联合在c-Met/sgAxin1模型中导致肿瘤消退。

要点

  • YAP/TAZ在c-Met/sgAxin1小鼠肝癌细胞中强烈诱导并为其肿瘤发生所必需。
  • c-Met/β-Catenin肝癌主要依赖YAP,YAP/TAZ缺失对其影响较轻。
  • AXIN1结合YAP/TAZ并调控其稳定性,遗传删除YAP/TAZ可抑制已形成的c-Met/sgAxin1肝肿瘤。

核心结论

  • YAP/TAZ是LOF AXIN1突变肝癌下游的主要信号分子,靶向YAP/TAZ是对抗AXIN1突变人肝癌的有效治疗策略。

研究设计与样本

  • 使用条件性Yap、Taz及Yap;Taz敲除小鼠分析c-Met/β-Catenin与c-Met/sgAxin1驱动肝癌对YAP/TAZ的需求。
  • 利用AXIN1突变肝癌细胞研究AXIN1调控YAP/TAZ的机制。
  • 应用肝细胞特异性可诱导TTR-CreER T2KO系统评估Yap;Taz在肿瘤进展中的作用。
  • 在体外和体内测试卡博替尼与G007-LK联合治疗。

主要发现

  • c-Met/sgAxin1小鼠肝癌细胞中核YAP/TAZ强烈诱导。
  • 过表达Lats2或同时删除Yap和Taz显著抑制c-Met/sgAxin1驱动肝癌发展,而对c-Met/β-Catenin肝癌影响较轻。
  • YAP是c-Met/β-Catenin肝癌的主要Hippo效应分子,YAP和TAZ均为c-Met/sgAxin1依赖的肝癌发生所必需。
  • AXIN1在人肝癌细胞中结合YAP/TAZ并调控其稳定性。
  • 遗传删除YAP/TAZ抑制已形成的c-Met/sgAxin1肝肿瘤,支持YAP/TAZ在肿瘤进展中的需求。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Gain-of-function (GOF) mutations of CTNNB1 and loss-of-function (LOF) mutations of AXIN1 are recurrent genetic alterations in hepatocellular carcinoma (HCC). We aim to investigate the functional contribution of Hippo/YAP/TAZ in GOF CTNNB1 or LOF AXIN1 mutant HCCs. APPROACH AND RESULTS: The requirement of YAP/TAZ in c-Met/β-Catenin and c-Met/sgAxin1-driven HCC was analyzed using conditional Yap , Taz , and Yap;Taz knockout (KO) mice. Mechanisms of AXIN1 in regulating YAP/TAZ were investigated using AXIN1 mutated HCC cells. Hepatocyte-specific inducible TTR-CreER T2KO system was applied to evaluate the role of Yap;Taz during tumor progression. Cabozantinib and G007-LK combinational treatment were tested in vitro and in vivo . Nuclear YAP/TAZ was strongly induced in c-Met/sgAxin1 mouse HCC cells. Activation of Hippo via overexpression of Lats2 or concomitant deletion of Yap and Taz significantly inhibited c-Met/sgAxin1 driven HCC development, whereas the same approaches had mild effects in c-Met/β-Catenin HCCs. YAP is the major Hippo effector in c-Met/β-Catenin HCCs, and both YAP and TAZ are required for c-Met/sgAxin1-dependent hepatocarcinogenesis. Mechanistically, AXIN1 binds to YAP/TAZ in human HCC cells and regulates YAP/TAZ stability. Genetic deletion of YAP/TAZ suppresses already formed c-Met/sgAxin1 liver tumors, supporting the requirement of YAP/TAZ during tumor progression. Importantly, tankyrase inhibitor G007-LK, which targets Hippo and Wnt pathways, synergizes with cabozantinib, a c-MET inhibitor, leading to tumor regression in the c-Met/sgAxin1 HCC model. CONCLUSIONS: Our studies demonstrate that YAP/TAZ are major signaling molecules downstream of LOF AXIN1 mutant HCCs, and targeting YAP/TAZ is an effective treatment against AXIN1 mutant human HCCs.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Liang B, Wang H, Qiao Y, et al. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis. Hepatology. 2022. PMID: 35921500. doi:10.1002/hep.32693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。